CorMedix (CRMD) Earnings Expected to Grow: What to Know Ahead of Q2 Release

Core Insights - CorMedix (CRMD) is anticipated to report a year-over-year increase in earnings driven by higher revenues for the quarter ended June 2025, with a consensus EPS estimate of $0.20, reflecting a +180% change [1][3] - Revenues are projected to reach $36.82 million, representing a significant increase of 4445.7% compared to the same quarter last year [3] Earnings Expectations - The stock may experience upward movement if the actual earnings exceed expectations, while a miss could lead to a decline [2] - The consensus EPS estimate has been revised down by 2.9% over the last 30 days, indicating a reassessment by analysts [4] Earnings Surprise Prediction - CorMedix has a positive Earnings ESP of +27.12%, suggesting analysts are optimistic about the company's earnings prospects [12] - The company holds a Zacks Rank of 1, indicating a strong likelihood of beating the consensus EPS estimate [12] Historical Performance - In the last reported quarter, CorMedix exceeded the expected earnings of $0.25 per share by delivering $0.30, resulting in a +20.00% surprise [13] - Over the past four quarters, CorMedix has consistently beaten consensus EPS estimates [14] Industry Comparison - Kymera Therapeutics, another player in the medical sector, is expected to report a loss of $0.74 per share, marking a year-over-year decline of -27.6% [18] - Kymera's revenues are projected at $34.46 million, up 34.4% from the previous year, but it has a negative Earnings ESP of -35.92% [19][20]